Trial reportJAMA network open2026
A Hybrid Lifestyle Program and Metabolic Health in Adults With Obesity: The PRAMEV Randomized Clinical Trial.
Trial report in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Obesity disproportionately affects low- and middle-income countries, where access to structured, scalable treatment remains limited. Objective: To evaluate whether a hybrid-format, intensive lifestyle modification program combined with usual medical care promotes a minimum weight loss of 5% in adults with obesity compared with usual medical care alone. Design, Setting, and Participants: This open-label, parallel-group, superiority randomized clinical trial recruited adults with a body mass index of 30 or greater from a tertiary public hospital in São Paulo, Brazil, between January 1 and March 31, 2022, randomized 1:1 to PRAMEV (Advanced Program for Intensive Lifestyle Modification) or control. Data were analyzed from May to September 2025 using an intention-to-treat approach. Interventions: PRAMEV was a 20-week, hybrid lifestyle intervention that included group-based behavioral counseling, nutritional education, physical activity promotion, and continuous instructor support. The control group received usual medical care. Main Outcomes and Measures: The primary outcome was the proportion of participants achieving a 5% or greater reduction in body weight assessed by bioelectrical impedance analysis at 20 weeks. Secondary outcomes included changes in weight, body mass index, waist circumference, metabolic parameters (lipid profile, glucose, and liver enzyme levels), dietary intake, and psychosocial variables. Results: A total of 200 participants (mean [SD] age, 47.9 [14.0] years; 172 [86.0%] women) were randomized to PRAMEV (n = 97) or control (n = 103). At 20 weeks, 143 participants (71.4%) completed follow-up, with higher dropout in the PRAMEV arm vs the control arm (39.2% [38 of 97] vs 21.4% [22 of 103]; P = .008). In the intention-to-treat analysis, groups did not differ in achieving 5% or greater weight loss (20.6% [20 of 97] vs 15.5% [16 of 103]; odds ratio, 1.34; 95% CI, 0.61-2.92; P = .46). Per-protocol analyses showed greater weight loss and improved anthropometric outcomes in the PRAMEV arm. The intervention improved the lipid profile, with reductions in liver enzyme and triglyceride levels and favorable changes in cholesterol fractions. No serious adverse events were reported. Conclusions and Relevance: In this randomized clinical trial of 200 adults with obesity receiving care in Brazil's public health care system, a hybrid-format lifestyle intervention did not improve the likelihood of achieving 5% or greater weight loss in the intention-to-treat analysis. However, secondary and per-protocol analyses suggested potential cardiometabolic benefits among adherent participants, warranting further investigation. Trial Registration: ReBEC Identifier: U1111-1273-8313.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.